Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids.
2D and 3D cell culture
Gene expression and BRAF inhibitor resistance
Melanoma cell lines
Spheroids
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
14
04
2020
accepted:
08
06
2020
pubmed:
3
7
2020
medline:
22
6
2021
entrez:
3
7
2020
Statut:
ppublish
Résumé
In vitro cell cultures are frequently used to define the molecular background of drug resistance. The majority of currently available data have been obtained from 2D in vitro cultures, however, 3D cell culture systems (spheroids) are more likely to behave similarly to in vivo conditions. Our major aim was to compare the gene expression signature of 2D and 3D cultured BRAFV600E mutant melanoma cell lines. We successfully developed BRAF-drug resistant cell lines from paired primary/metastatic melanoma cell lines in both 2D and 3D in vitro cultures. Using Affymetrix Human Gene 1.0 ST arrays, we determined the gene expression pattern of all cell lines. Our analysis revealed 1049 genes (562 upregulated and 487 downregulated) that were differentially expressed between drug-sensitive cells grown under different cell cultures. Pathway analysis showed that the differently expressed genes were mainly associated with the cell cycle, p53, and other cancer-related pathways. The number of upregulated genes (72 genes) was remarkably fewer when comparing the resistant adherent cells to cells that grow in 3D, and were associated with cell adhesion molecules and IGF1R signalling. Only 1% of the upregulated and 5.6% of the downregulated genes were commonly altered between the sensitive and the resistant spheroids. Interestingly, we found several genes (BNIP3, RING1 and ABHD4) with inverse expression signature between sensitive and resistant spheroids, which are involved in anoikis resistance and cell cycle regulation. In summary, our study highlights gene expression alterations that might help to understand the development of acquired resistance in melanoma cells in tumour tissue.
Identifiants
pubmed: 32613561
doi: 10.1007/s12253-020-00837-9
pii: 10.1007/s12253-020-00837-9
pmc: PMC7471197
doi:
Substances chimiques
Protein Kinase Inhibitors
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2557-2566Références
ChemMedChem. 2014 Apr;9(4):792-7
pubmed: 24574257
Curr Pharm Des. 2018;24(15):1689-1694
pubmed: 29623827
Oncotarget. 2018 Apr 3;9(25):17631-17644
pubmed: 29707136
J Cell Physiol. 2005 Aug;204(2):522-31
pubmed: 15744745
Oncogene. 2009 Jul 30;28(30):2697-709
pubmed: 19483722
Cancer Discov. 2014 Jan;4(1):94-109
pubmed: 24265153
J Exp Clin Cancer Res. 2019 Mar 1;38(1):108
pubmed: 30823889
J Skin Cancer. 2013;2013:537028
pubmed: 23762562
Melanoma Res. 2012 Dec;22(6):466-72
pubmed: 22584957
Exp Oncol. 2015 Mar;37(1):77-80
pubmed: 25804238
Mater Sci Eng C Mater Biol Appl. 2020 Feb;107:110264
pubmed: 31761183
Nucleic Acids Res. 2018 Nov 2;46(19):10007-10018
pubmed: 30053102
Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498
pubmed: 23830918
J Invest Dermatol. 2015 Feb;135(2):532-541
pubmed: 25243790
Melanoma Res. 2017 Jun;27(3):180-188
pubmed: 28234767
Arch Med Sci. 2018 Jun;14(4):910-919
pubmed: 30002710
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8838-43
pubmed: 24876273
Cancer Res. 2017 Oct 15;77(20):5445-5451
pubmed: 28807941
Endocr Relat Cancer. 2020 Feb;27(2):111-121
pubmed: 31804972
Analyst. 2011 Feb 7;136(3):473-8
pubmed: 20967331
Melanoma Res. 2019 Aug;29(4):390-400
pubmed: 30741840
Cancer Res. 2003 Sep 15;63(18):5691-6
pubmed: 14522885
Oncotarget. 2016 May 10;7(19):28697-710
pubmed: 26885690
Nat Cell Biol. 2002 Feb;4(2):95-105
pubmed: 11788820
Cancer Res. 2006 Oct 1;66(19):9437-44
pubmed: 17018598
Oncotarget. 2016 Jul 19;7(29):45745-45756
pubmed: 27304190
Cell Death Dis. 2014 Mar 13;5:e1127
pubmed: 24625986
Kaohsiung J Med Sci. 2015 Nov;31(11):553-61
pubmed: 26678934
Int J Mol Sci. 2015 Mar 11;16(3):5517-27
pubmed: 25768338
Pigment Cell Melanoma Res. 2015 May;28(3):330-9
pubmed: 25475071
J Clin Pathol. 2013 Aug;66(8):644-8
pubmed: 23526597
Physiology (Bethesda). 2017 Jul;32(4):266-277
pubmed: 28615311
PLoS One. 2017 Aug 23;12(8):e0183689
pubmed: 28832687
Onco Targets Ther. 2018 Oct 17;11:7095-7107
pubmed: 30410366
Biomed Pharmacother. 2019 Jan;109:2548-2560
pubmed: 30551515
Nat Immunol. 2019 Feb;20(2):206-217
pubmed: 30664764
Cancer Metastasis Rev. 2016 Mar;35(1):93-107
pubmed: 26970965
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
J Invest Dermatol. 2009 Dec;129(12):2843-53
pubmed: 19554017
Pediatr Surg Int. 2008 Nov;24(11):1229-34
pubmed: 18797883
Cancer Manag Res. 2018 May 01;10:969-976
pubmed: 29760566
Assay Drug Dev Technol. 2016 Jan-Feb;14(1):19-28
pubmed: 26866750
Semin Cancer Biol. 2005 Oct;15(5):405-12
pubmed: 16055341
Oncogene. 2016 Apr 28;35(17):2166-77
pubmed: 26279295
Int J Mol Med. 2011 Nov;28(5):721-6
pubmed: 21743955
Mol Ther Nucleic Acids. 2018 Sep 7;12:861-871
pubmed: 30161025
Int J Mol Sci. 2019 Aug 29;20(17):
pubmed: 31470659
Melanoma Res. 2018 Dec;28(6):536-546
pubmed: 30124539
Anal Methods. 2019 Sep 7;11(33):4220-4232
pubmed: 32051693
Apoptosis. 2012 Jul;17(7):666-78
pubmed: 22488300
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514305
ACS Biomater Sci Eng. 2018 Feb 12;4(2):410-420
pubmed: 29527571
Biomaterials. 2020 Feb;232:119744
pubmed: 31918229
Crit Rev Eukaryot Gene Expr. 2017;27(1):53-62
pubmed: 28436332
Biomol Ther (Seoul). 2019 May 1;27(3):302-310
pubmed: 30293252
Oncotarget. 2016 Mar 22;7(12):15065-92
pubmed: 26918341
BMC Genomics. 2006 Jan 11;7:3
pubmed: 16405732
Melanoma Res. 2010 Apr;20(2):97-106
pubmed: 20179655